Catalyst
Slingshot members are tracking this event:
Omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections to report top-line data in mid-2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 16, 2016
Occurred Source:
http://investor.paratekpharm.com/phoenix.zhtml?c=253770&p=irol-newsArticle_Print&ID=2178166
Related Projects
- Following up on Omadacycline's success in the Phase 3 study in Acute Bacterial Skin Infections. Now that the asset is de-risked, what is it worth? PRTK, CEMP Executed On: Sep 16, 2016 at 09:00 AM EDT
Related Keywords
Omadacycline, Acute Bacterial Skin Infection, Skin Structure Infection, Top-line Data, Bacterial Resistance
